The Food and Drug Administration on Wednesday approved a new drug test for CBD, a non-psychoactive cannabis extract.
The approval by the agency follows approval by an advisory panel earlier this month that also recommended approving the test.
The drug test will allow patients with a specific condition to be treated with CBD without using marijuana.CBD is currently the only federally approved treatment for patients with epilepsy.
The drug has also been approved for the treatment of some forms of cancer, HIV and other diseases.
The agency’s decision to approve the CBD drug test comes on the heels of other recent FDA approval of CBD for epilepsy.
In November, the FDA approved a CBD test that can detect cannabidiol (CBD), a compound found in cannabis.
This test, the first approved for CBD testing, also helps to monitor how patients are using the drug.
The FDA said in the agency’s announcement that CBD tests have proven useful in assessing the safety and efficacy of CBD products.
The first CBD test was approved in 2014 for the screening of patients with certain medical conditions, such as epilepsy, and it can be administered to individuals with certain conditions such as cancer, Alzheimer’s disease, and glaucoma.
The CBD test is not meant to diagnose the condition, and the FDA is not recommending it.
The new CBD test will be administered at a pharmacy as part of the FDA’s approval process.
It will be available in the United States for those age 18 or older, according to the agency.
The test has been designed to detect cannibidiol, the active ingredient in cannabis that has been shown to have therapeutic benefits in patients with seizure disorders.